Multiple Sclerosis Drugs - Brazil

Brazil

Highlights

The Multiple Sclerosis Drugs market in Brazil is anticipated to achieve a revenue of US$378.40m in 2024.
It is forecasted to exhibit a compound annual growth rate (CAGR 2024-2029) of 1.49%, leading to a market volume of US$407.50m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$11.77bn in 2024.
Brazil's growing pharmaceutical industry is driving an increase in availability and accessibility of multiple sclerosis drugs in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Multiple Sclerosis Drugs market in Brazil has been steadily growing in recent years.

Customer preferences: Patients in Brazil are increasingly seeking better treatment options for Multiple Sclerosis (MS), a chronic autoimmune disease that affects the central nervous system. They are looking for drugs that can not only manage the symptoms of the disease but also slow down its progression. Additionally, there is a growing demand for drugs that have fewer side effects and are more affordable.

Trends in the market: One of the main trends in the Multiple Sclerosis Drugs market in Brazil is the increasing use of disease-modifying therapies (DMTs). These drugs can reduce the number of relapses and slow down the progression of the disease. Another trend is the growing popularity of oral medications, which are more convenient for patients than injectable drugs. There is also a trend towards personalized medicine, with drugs being tailored to the patient's specific needs.

Local special circumstances: One of the unique aspects of the Multiple Sclerosis Drugs market in Brazil is the high prevalence of the disease in the country. Brazil has one of the highest rates of MS in the world, with an estimated 35,000 to 45,000 cases. This has led to a greater awareness of the disease and a greater demand for effective treatments. Additionally, Brazil has a strong public healthcare system that provides free or low-cost treatment to patients, which has helped to increase access to MS drugs.

Underlying macroeconomic factors: The Brazilian economy has been recovering from a recession in recent years, which has led to an increase in healthcare spending. This has helped to boost the Multiple Sclerosis Drugs market in the country. Additionally, there is a growing middle class in Brazil that has more disposable income to spend on healthcare. However, the market is also facing challenges such as high taxes and regulatory barriers, which can make it difficult for companies to enter the market and for patients to access drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.